NEW YORK (GenomeWeb) – HTG Molecular Diagnostics reported after the close of the market on Monday that its first quarter revenues saw a 62 percent bump year over year in spite of a slowdown in product sales.

For the three months ended March 31, the firm reported $1.4 million in total revenues, compared to $865,232 in the year-ago period. While service revenues grew to $830,025 in Q1 2017 from $265,042 in Q1 2016, product revenues slid to $541,144 from $600,190.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.